Adverum Biotechnologies (STU:AVU0) 5-Year EBITDA Growth Rate : -3.60% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Adverum Biotechnologies 5-Year EBITDA Growth Rate?

Adverum Biotechnologies's EBITDA per Share for the three months ended in Mar. 2024 was €-2.34.

During the past 3 years, the average EBITDA Per Share Growth Rate was 4.20% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -3.60% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -5.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Adverum Biotechnologies was 15.60% per year. The lowest was -172.00% per year. And the median was -0.90% per year.

Competitive Comparison of Adverum Biotechnologies's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Adverum Biotechnologies's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adverum Biotechnologies's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adverum Biotechnologies's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Adverum Biotechnologies's 5-Year EBITDA Growth Rate falls into.

Adverum Biotechnologies 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Adverum Biotechnologies (STU:AVU0) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Adverum Biotechnologies 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Adverum Biotechnologies's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Adverum Biotechnologies (STU:AVU0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adverum Biotechnologies Inc (STU:AVU0) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

ADVM:USA

Address

100 Cardinal Way, Redwood CIty, CA, USA, 94063

Website

https://www.adverum.com

Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

Adverum Biotechnologies (STU:AVU0) Headlines

No Headlines